BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38158850)

  • 1. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan.
    Yagi A; Nakagawa S; Ueda Y; Oka E; Ikeda S; Kakuda M; Kobayashi E; Ito Y; Katayama K; Hirai K; Nakayama T; Kimura T
    Cancer Sci; 2024 Mar; 115(3):916-925. PubMed ID: 38158850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation.
    Ishimoto T; Yagi A; Nakajima K; Okamoto N; Yukimitsu E; Kawasaki M; Kawae Y; Hayasaka S; Ueda Y; Kimura T
    Hum Vaccin Immunother; 2023 Aug; 19(2):2229222. PubMed ID: 37462048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intentions for catch-up HPV vaccination in Japan: an internet survey.
    Nakagawa S; Yagi A; Ueda Y; Ikeda S; Kakuda M; Hiramatsu K; Miyoshi A; Kimura T; Hirai K; Sekine M; Nakayama T; Kobayashi E; Miyagi E; Enomoto T; Kimura T
    Int J Clin Oncol; 2023 Dec; 28(12):1667-1679. PubMed ID: 37776388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan.
    Nakagawa S; Ueda Y; Yagi A; Ikeda S; Hiramatsu K; Kimura T
    Cancer Sci; 2020 Jun; 111(6):2156-2162. PubMed ID: 32248632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Catch-Up Vaccinations Fill the Void Left by Suspension of the Governmental Recommendation of HPV Vaccine in Japan?
    Yagi A; Ueda Y; Nakagawa S; Ikeda S; Kakuda M; Hiramatsu K; Miyoshi A; Kobayashi E; Kimura T; Mizushima T; Suzuki Y; Sekine M; Hirai K; Nakayama T; Miyagi E; Enomoto T; Kimura T
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
    Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
    Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered.
    Yagi A; Ueda Y; Oka E; Nakagawa S; Kimura T; Shimoya K
    Cancer Sci; 2024 May; ():. PubMed ID: 38698561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The last strategy for re-dissemination of HPV vaccination in Japan while still under the suspension of the governmental recommendation.
    Ueda Y; Yagi A; Abe H; Nakagawa S; Minekawa R; Kuroki H; Miwa A; Kimura T
    Sci Rep; 2020 Sep; 10(1):16091. PubMed ID: 32999408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of future cervical cancer risk in Japan, based on birth year.
    Yagi A; Ueda Y; Ikeda S; Sekine M; Nakayama T; Miyagi E; Enomoto T
    Vaccine; 2019 May; 37(22):2889-2891. PubMed ID: 31027925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
    Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
    Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
    Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
    J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for cervical cancer incidence and death resulting from Japan's current policy of prolonged suspension of its governmental recommendation of the HPV vaccine.
    Yagi A; Ueda Y; Nakagawa S; Ikeda S; Tanaka Y; Sekine M; Miyagi E; Enomoto T; Kimura T
    Sci Rep; 2020 Sep; 10(1):15945. PubMed ID: 32994516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.
    Simms KT; Hanley SJB; Smith MA; Keane A; Canfell K
    Lancet Public Health; 2020 Apr; 5(4):e223-e234. PubMed ID: 32057317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities among Japanese municipalities in recommendations for routine and catch-up HPV vaccinations.
    Watanabe Y; Ueda Y; Yagi A; Ikeda S; Oka E; Kakuda M; Nakagawa S; Hiramatsu K; Miyoshi A; Kobayashi E; Kimura T; Kimura T
    Cancer Sci; 2023 May; 114(5):2139-2144. PubMed ID: 36747329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection.
    Choi W; Shim E
    Prev Med; 2024 Jan; 178():107743. PubMed ID: 37866695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Realistic fear of cervical cancer risk in Japan depending on birth year.
    Yagi A; Ueda Y; Egawa-Takata T; Tanaka Y; Nakae R; Morimoto A; Terai Y; Ohmichi M; Ichimura T; Sumi T; Murata H; Okada H; Nakai H; Mandai M; Matsuzaki S; Kobayashi E; Yoshino K; Kimura T; Saito J; Hori Y; Morii E; Nakayama T; Suzuki Y; Motoki Y; Sukegawa A; Asai-Sato M; Miyagi E; Yamaguchi M; Kudo R; Adachi S; Sekine M; Enomoto T; Horikoshi Y; Takagi T; Shimura K
    Hum Vaccin Immunother; 2017 Jul; 13(7):1700-1704. PubMed ID: 28272968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study.
    Tozawa-Ono A; Kamada M; Teramoto K; Hareyama H; Kodama S; Kasai T; Iwanari O; Koizumi T; Ozawa N; Suzuki M; Kinoshita K
    Hum Vaccin Immunother; 2021 Apr; 17(4):950-954. PubMed ID: 33121340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.